Targacept NNR Drug Development Is Smokin’ After GSK Cash Infusion
Glaxo partners with Targacept in potential $1.5 billion deal on neuronal nicotinic receptor therapeutics for pain, smoking cessation, obesity, addiction and Parkinson’s.
Glaxo partners with Targacept in potential $1.5 billion deal on neuronal nicotinic receptor therapeutics for pain, smoking cessation, obesity, addiction and Parkinson’s.